Description
The Practicing Oncologists Working Group is pleased to present a new series of Spotlight articles featuring highlights from the ESMO 2021 Congress.
Watch the presentations and make sure you keep up to date on the key practice changing outcomes from this year's annual meeting.
Produced by the Practising Oncologists Working Group
Featured abstracts
LBA1 - Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (Pts) with HER2+ metastatic breast cancer (mBC): Results of the randomized phase III DESTINY-Breast03 study
Presenter: Javier Cortés - Session: Presidential symposium 1
Abstract, slides and webcast
LBA16 - KEYNOTE-355: Final results from a randomized, double-blind phase III study of first-line pembrolizumab + chemotherapy vs placebo + chemotherapy for metastatic TNBC
Presenter: Hope Rugo - Session: Proffered Paper session - Breast cancer, metastatic
Abstract, slides and webcast
VP7_2021 - KEYNOTE-522: Phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy as neoadjuvant treatment, followed by pembrolizumab vs placebo as adjuvant treatment for early triple-negative breast cancer (TNBC)
Presenter: Peter Schmid - Session: Virtual Plenary Debate
Abstract, slides and webcast
LBA11 - Individual patient data meta-analysis of 5 non-inferiority RCTs of reduced duration single agent adjuvant trastuzumab in the treatment of HER2 positive early breast cancer
Presenter: Helena Earl - Session: Proffered Paper session - Breast cancer, early stage
Abstract, slides and webcast
